...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots
【24h】

Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots

机译:开发和验证用于定量血浆和干燥血浆斑点中粘菌素的UHPLC-MS / MS方法

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Quantification of colistin in plasma samples may be very useful in optimizing therapy especially in special patients' population. Nevertheless, therapeutic drug monitoring of colistin is still limited probably for the low number of laboratories which perform this analysis and for high shipment costs. We developed and validated new UHPLC-MS/MS methods to quantify colistin in plasma and in dried plasma spots (DPS) collected on dried sample spots devices (DSSD). Colistin A, Colistin B and polimixin B, used as internal standard, were detected using multiple reaction monitoring (MRM) of the following specific transitions: 585.5 -> 534.9; 576, 578.5 -> 527.9; 568.9 and 602.5 -> 100.9, 551.9,592.8, respectively. Colistin A and B were extracted from plasma using protein precipitation and from DSSD using an extraction basic solution. Both methods were validated, and the mean intra and inter-day accuracies and precisions were in accordance with FDA and EMA guidelines. Colistin in DPS was found to be stable for at least one week at room temperature (20-25 degrees C). A statistically significant linear correlation was found between colistin extracted from plasma and from DPS [r(2) 0.9864 (P < 0.0001, 95% CI 0.9699-0.9939) for colistin A and 0.9695 (P <0.0001, 95% CI 0.9310-0.9866) for colistin B, respectively]. DPS on DSSD represents a safe and cheap strategy to store and ship at room temperature plasma samples. Thus, it is suited for pharmacokinetic studies and therapeutic drug monitoring of colistin. (C) 2016 Elsevier B.V. All rights reserved.
机译:血浆样品中大肠粘菌素的定量对优化治疗尤其有用,特别是在特殊患者人群中。尽管如此,对粘菌素的治疗药物监测仍然可能由于执行该分析的实验室数量少和运输成本高而受到限制。我们开发并验证了新的UHPLC-MS / MS方法,以定量测定血浆和干样品斑点设备(DSSD)上收集的干血浆斑点(DPS)中的粘菌素。使用以下特定转变的多重反应监测(MRM)检测了用作内标的共利斯汀A,共利斯汀B和多菌素B:585.5-> 534.9; 576,578.5-> 527.9; 568.9和602.5-> 100.9、551.9、592.8。使用蛋白沉淀从血浆中提取Colistin A和B,使用提取碱性溶液从DSSD中提取Colistin A和B。两种方法均已验证,平均日间和日间精度和精确度符合FDA和EMA指南。发现DPS中的共利斯汀在室温(20-25摄氏度)下稳定至少一周。发现从血浆和DPS提取的大肠菌素之间存在统计学上显着的线性相关性[大肠菌素A的r(2)0.9864(P <0.0001,95%CI 0.9699-0.9939)和0.9695(P <0.0001,95%CI 0.9310-0.9866)分别针对粘菌素B]。 DSSD上的DPS代表了一种安全廉价的策略,可以在室温下存储和运输血浆样品。因此,它适用于粘菌素的药代动力学研究和治疗药物监测。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号